[Form 4] KEWAUNEE SCIENTIFIC CORP /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.

Positive

• None.

Negative

• Insider sales: 652 shares sold on 09/18/2025 at a weighted average price of $46 (range $46.00–$46.03).
• Insider sales: 773 shares sold on 09/19/2025 at a weighted average price of $45.34 (range $45.21–$45.71).
• Reduced reported beneficial ownership: beneficial ownership reported at 43,294 shares following the 09/19/2025 transaction.

Insights

Financial Analyst

TL;DR: The CEO/director reported modest, consecutive-day stock sales totaling 1,425 shares at ~$45–$46 per share; ownership remained tens of thousands of shares.

The filings show two open-market dispositions by the company’s President and CEO: 652 shares sold on 09/18/2025 at a weighted average of $46 and 773 shares sold on 09/19/2025 at a weighted average of $45.34. Beneficial ownership after the second sale is reported at 43,294 shares. These transactions are presented as sales with provided weighted average price ranges and no derivative activity disclosed. The amounts are small in absolute share count but are material to note for share-count trends; no additional company financial metrics or reasons for the sales are provided in the filing.

Corporate Governance Expert

TL;DR: Insider sales by a named executive were disclosed properly; filing includes weighted-average pricing disclosures and attorney-in-fact signature.

The Form 4 identifies Thomas David Hull III as both an officer (President, CEO) and director, and reports two non-derivative sale transactions on consecutive dates with explanatory remarks specifying weighted-average price ranges. The form is signed by an attorney-in-fact, indicating authorized electronic or delegated filing. There is no indication of Rule 10b5-1 plan checkbox selection in the presented text, and no amendment noted. From a governance and compliance perspective, the disclosure meets basic Form 4 content requirements; the filing does not state any company action or additional governance events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HULL THOMAS DAVID III

(Last) (First) (Middle)

2700 WEST FRONT STREET

(Street)

STATESVILLE NC 28677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2025		S		652	D	$46(1)	44,067	D
Common Stock	09/19/2025		S		773	D	$45.34(2)	43,294	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reflects the weighted average purchase price of the transactions reported. The price range of such transactions was $46.00 to $46.03. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.

2. The price reflects the weighted average purchase price of the transactions reported. The price range of such transactions was $45.21 to $45.71. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Donald T. Gardner III, Attorney-in-fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did KEQU insider Thomas David Hull III report on Form 4?

The Form 4 reports two sales: 652 shares sold on 09/18/2025 at a weighted average price of $46 and 773 shares sold on 09/19/2025 at a weighted average price of $45.34.

How many shares does Thomas David Hull III report owning after these transactions?

The filing shows 44,067 shares beneficially owned after the 09/18/2025 sale and 43,294 shares beneficially owned after the 09/19/2025 sale.

Did the Form 4 disclose option or derivative transactions for KEQU?

No. Table II (derivative securities) contains no reported transactions; only non-derivative common stock sales are reported.

Are the reported prices exact transaction prices or weighted averages?

The filing states the reported prices are weighted average purchase prices with specified price ranges for each date; the reporting person offers to provide per-price breakdowns upon request.

Who signed the Form 4 for the reporting person?

The Form 4 is executed by /s/ Donald T. Gardner III, Attorney-in-fact with date 09/22/2025.

Does the filing indicate a 10b5-1 trading plan or amendment?

The presented text does not indicate that a 10b5-1 plan checkbox was selected and shows no amendment date other than the transactions themselves.